| Name | Title | Contact Details |
|---|
Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.
MYM Nutraceuticals Inc. (CSC:MYM) (OTC:MYMMF) (FRA:OMY) is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company`s board of directors and staff.
William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.